Can psychedelic-assisted psychotherapy revolutionize how we treat mental illness?
In short: For decades, psychedelic research was stifled by governments and shunned by academia. Now, researchers are exploring how compounds like psilocybin and MDMA can augment psychotherapy to treat PTSD, depression, and substance abuse, potentially offering hope to patients who do not benefit from current evidence-based treatments.
The field is currently navigating a complex regulatory landscape. Researchers were startled when an advisory panel recently declined to endorse MDMA-assisted psychotherapy for PTSD, despite expectations that it would be the first to receive FDA clearance. Lykos Therapeutics, which was the initial firm to provide clinical trial evidence for US market authorisation, was questioned on whether the advantages of pairing MDMA with psychotherapy surpassed the dangers, and if subjects could differentiate the therapy from a placebo. The panel specifically noted concerns regarding the company's failure to record certain participant data. For instance, they requested reports on euphoria to assess potential abuse risks.
Despite these setbacks, the momentum in the field is significant. Johns Hopkins Center for Psychedelic and Consciousness Research, backed by $55 million in funding, is leading efforts to develop tailored treatments for various psychiatric disorders and to explore how these substances support human thriving in healthy volunteers. Researchers like David Olson suggest that while regulatory hurdles may delay milestones, the 'train has left the station' for these molecules.
The mechanisms involve substances that trigger non-ordinary states of consciousness, altering perception, mood, and cognitive processes. Psilocybin, a naturally occurring compound in 'magic mushrooms,' can penetrate the central nervous system. Current research is investigating how these substances can augment psychotherapy, with ongoing clinical trials testing various compounds including psilocybin, LSD, and ibogaine for mental health conditions. Beyond psilocybin, researchers are also examining the therapeutic potential of LSD and ibogaine. These substances are currently being investigated for their ability to improve symptoms in various mental health conditions.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Rick Doblin: The future of psychedelic-assisted psychotherapy
- Also: Johns Hopkins Center for Psychedelic and Consciousness Research
- Also: Reeling from FDA setback, researchers plot the future of psychedelic-assisted medicine | Science | AAAS
- Also: Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD
To cite this card, link to https://intellectplus.co.uk/app/health-the-future-of-psychedelic-assisted-psychotherapy.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Psychiatry · More in Health · Latest · A–Z · All topics
